Searching for Ideal Oxazolidinone for Treatment of Tuberculosis
https://doi.org/10.58838/2075-1230-2026-104-1-114-125
Abstract
Oxazolidinones represent a promising class of drugs for treatment of multidrug-resistant tuberculosis (MDR-TB). Linezolid, the first representative of this class, is highly effective; however, its use is limited due to its toxicity (myelosuppression, neuropathy). 63 publications were analyzed in order to search for new oxazolidinones for treatment of tuberculosis. New drugs and compounds (tedizolid, sutezolid, contezolid, delpazolid, and TBI-223) have a more favorable safety profile with antimycobacterial activity similar to or even greater than that of linezolid. In the coming years, these compounds may become an important component of short, safe, and effective chemotherapy regimens for tuberculosis.
About the Authors
A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasiya I. Gayda, Candidate of Medical Sciences, Senior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections
2, 4 Dostoevskiy St., Moscow, 127473;
Phone: +7 (495) 681-11-66
G. N. Mozhokina
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Galina N. Mozhokina Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics and Tuberculosis Infection, Leading Researcher of Pharmacology and Chemotherapy
Laboratory
2, 4 Dostoevskiy St., Moscow, 127473;
Phone: +7 (495) 681-11-66
E. R. Pereverzeva
G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Eleonora R. Pereverzeva, Doctor of Biological Sciences, Chief Researcher
2, 4 Dostoevskiy St., Moscow, 127473:
Phone: +7 (495) 681-11-66
M. I. Romanova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Maria I. Romanova Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections
2, 4 Dostoevskiy St., Moscow, 127473;
Phone: +7 (495) 681-11-66
A. V. Abramchenko
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Anna V. Abramchenko, Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections Assistant of Phthisiology Department
2, 4 Dostoevskiy St., Moscow, 127473;
Phone: +7 (495) 681-11-66
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasiya G. Samoylova, Doctor of Medical Sciences, Deputy Director for Research
2, 4 Dostoevskiy St., Moscow, 127473;
Phone: +7 (495) 681-11-66
References
1. Amizolid (linezolid). Information about the medicinal product. (In Russ.) Epub. Available: https://yotta.vademec.ru/drugs/amizolid/Accessed June 14, 2025
2. Nikoda V.V., Kuznetsova S.M., Prusova A.S. Clinical and microbiological features of tedizolid, a new product from the oxazolidinone group. Pharmateka, 2017, no. 17, pp. 10. (In Russ.)
3. Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.)
4. Ali M.Z., Dutt T.S., MacNeill A., Walz A., Pearce C., Lam H., Philp J., Patterson J., Henao-Tamayo M., Lee R.E., Liu J., Robertson G.T., Hickey A.J., Meibohm B., Gonzalez-Juarrero M.A. Modified B.P.L. regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. bioRxiv, 2023, vol. 11, no. 16, pp. 567434. https://doi.org/ 10.1101/2023.11.16.567434
5. Alsultan A., Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Thiel B., Debanne S.A., Boom W.H., Diacon A.H., Johnson J.L., Peloquin C.A. Population pharmacokinetics of AZD-5847 in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2017, vol. 61, no. 10, pp. e01066-17. https://doi.org/10.1128/AAC.01066-17
6. Angula K.T., Legoabe L.J., Beteck R.M. Chemical classes presenting novel antituberculosis agents currently in different phases of drug development: a 2010-2020 review. Pharmaceuticals (Basel), 2021, vol. 14, no. 5, pp. 461. https://doi.org/10.3390/ph14050461
7. Application for addition of tedizolid phosphate to the WHO Model List of Essential Medicines.World Health Organization. EML Expert Committee Meeting, 2023. Available: https://list.essentialmeds.org/recommendations/1165 Accessed September 27, 2025
8. Assistance Publique – Hôpitaux de Paris. Evaluation of the Early Bactericidal Activity of Tedizolid Phosphate Compared with Linezolid and Standard Tuberculosis Therapy in Adult Patients with Drug-Susceptible Pulmonary Tuberculosis: clinical trial NCT05534750. Available: ClinicalTrials.gov Accessed July 24, 2025
9. Balasubramanian V., Solapure S., Iyer H., Ghosh A., Sharma S., Kaur P., Deepthi R., Subbulakshmi V., Ramya V., Ramachandran V., Balganesh M., Wright L., Melnick D., Butler S.L., Sambandamurthy V.K. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 1, pp. 495-502. https://doi.org/10.1128/AAC.01903-13
10. Barbachyn M.R., Hutchinson D.K., Brickner S.J., Cynamon M.H., Kilburn J.O., Klemens S.P., Glickman S.E., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., Zurenko G.E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem., 1996, vol. 39, no. 3, pp. 680-685. https://doi.org/10.1021/jm950956y
11. Bruinenberg P., Nedelman J., Yang T.J., Pappas F., Everitt D. Single ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of sutezolid in healthy adult subjects. Antimicrob. Agents Chemother., 2022, vol. 66, no. 4, pp. e0210821. https://doi.org/10.1128/aac.02108-21
12. Chen R.H., Burke A., Cho J.G., Alffenaar J.W., Davies Forsman L. New oxazolidinones for tuberculosis: are novel treatments on the horizon? Pharmaceutics, 2024, vol. 16, no. 6. https://doi.org/10.3390/pharmaceutics16060818
13. Cho Y.L., Jang J. Development of delpazolid for the treatment of tuberculosis. Applied Sciences, 2020, vol. 10, no. 7, pp. 2211. https://doi.org/10.3390/app10072211
14. Cho Y.S., Lim H.S., Lee S.H., Cho Y.L., Nam H.S., Bae K.S. et al. Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers. Antimicrob. Agents Chemother., 2018, vol. 62, no. 7, pp. se00451-se00518. https://doi.org/10.1128/AAC.00451-18
15. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva, World Health Organization, 2014 (WHO/HTM/TB/2014.11) Available: apps.who.int Accessed September 10, 2025
16. Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R. McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M.; ZeNix Trial Team. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med., 2022, vol. 387, no. 9, pp. 810-823. https://doi.org/10.1056/NEJMoa2119430
17. Contezolid (MRX-I) clinical trials for bone and joint and tuberculosis treatment. DrugBank. Available:https://go.drugbank.com Accessed June 16, 2025
18. Delpazolid (LCB01-0371). MedPath. Available: https://trial.medpath.com Accessed June 27, 2025
19. Deshpande D., Srivastava S., Nuermberger E., Koeuth T., Martin K.R., Cirrincione K.N., Lee P.S., Gumbo T. Multiparameter Responses to tedizolid monotherapy and moxifloxacin combination therapy models of children with intracellular tuberculosis. Clin. Infect. Dis., 2018, vol. 67, S3, pp. 342-S348. https://doi.org/10.1093/cid/ciy612
20. Dierig A., Hoelscher M., Schultz S., Hoffmann L., Jarchow-MacDonald A., Svensson E.M., Te Brake L., Aarnoutse R., Boeree M., McHugh T.D., Wildner L.M., Gong X., Phillips P., Minja L.T., Ntinginya N., Mpagama S., Liyoyo A., Wallis R.S., Sebe M., Mhimbira F.A., Mbeya B., Rassool M., Geiter L., Cho Y.L., Heinrich N. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials, 2023, vol. 24, no. 1, pp. 382. https://doi.org/10.1186/s13063-023-07354-5
21. Dong J., Cheng Q., Tang C., Zhong Y., Wang J., Lv M., Chen Z., Li P., Luo M., Pei H. Comparative in vitro drug susceptibility study of five oxazolidinones against Mycobacterium tuberculosis in Hainan, China. Pathogens, 2025, vol. 14, no. 3, pp. 218. https://doi.org/10.3390/pathogens14030218
22. Fernandes G.F.S., Scarim C.B., Kim S.H., Wu J., Castagnolo D. Oxazolidinones as versatile scaffolds in medicinal chemistry. RSC Med. Chem., 2023, vol. 14, no. 5, pp. 823-847. https://doi.org/10.1039/d2md00415a
23. Flanagan S., Bartizal K., Minassian S.L., Fang E., Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother., 2013, vol. 57, no. 7, pp. 3060-3066. https://doi.org/ 10.1128/AAC.00431-13
24. Flanagan S., McKee E.E., Rastogi N.K., Talley A.K., Fang E., Baker T.M., Marr J., Stryjewski M.E., Prokocimer P. Nonclinical and clinical evidence that tedizolid phosphate is safe with potentially less myelosuppression than linezolid. Antimicrobial Agents and Chemotherapy, 2015, vol. 59, no. 11, pp. 6472-6480. https://doi.org/10.1128/AAC.00916-15;
25. Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Peloquin C.A., Alsultan A., Thiel B.A., Debanne S.M., Boom W.H., Diacon A.H., Johnson J.L. Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2016, vol. 60, no. 11, pp. 6591-6599. https://doi.org/10.1128/AAC.01163-16
26. Gao T., Yao C., Shang Y., Su R. Zhang X., Ren W., Li S., Shu W., Pang Y., Li Q. Antimicrobial effect of oxazolidinones and its synergistic effect with bedaquiline against Mycobacterium abscessus complex. Infect Drug Resist., 2023, vol. 14, no. 16, pp. 279-287. https://doi.org/10.2147/IDR.S395750
27. History. LegoChem Biosciences. Orphan Drug (07.2017) и Fast Track (01.2018) from FDA. Available: https://www.legochembio.com Accessed June 10, 2025
28. Iqbal K., Milioudi A., Wicha S.G. Pharmacokinetics and pharmacodynamics of tedizolid. Clin. Pharmacokinet., 2022, vol. 61, no. 4, pp. 489-503. https://doi.org/10.1007/s40262-021-01099-7
29. Jeong J.W., Jung S.J., Lee H.H., Kim Y.Z., Park T.K., Cho Y.L. et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob. Agents Chemother., 2010, vol. 54, no. 12, pp. 5359-5362. https://doi.org/10.1128/AAC.00723-10
30. Johnson T.M., Rivera C.G., Lee G., Zeuli J.D. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. J. Clin. Tuberc. Other Mycobact. Dis., 2024, no. 37.1, pp. 00470. https://doi.org/10.1016/j.jctube.2024.100470
31. Kim J.S., Kim Y.H., Lee S.H., Kim Y.H., Kim J.W., Kang J.Y. et al. Early bactericidal activity of delpazolid (LCB01-0371) in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2022, vol. 66, no. 2, pp. e01684-21. https://doi.org/10.1128/AAC.01684-21
32. Kim T., Chang I., Kwon H., Kim M., Lee S., Park Y., Kim S. Pharmacokinetics, toxicity, and tolerability of tedizolid phosphate: results from a bridging study in healthy Korean subjects. Infection & Chemotherapy, 2017, vol. 49, no. 3, pp. 198-205. https://doi.org/10.3947/ic.2017.49.3.198
33. Kim T.S., Choe J.H., Kim Y.J., Yang C.S., Kwon H.J., Jeong J., Kim G., Park D.E., Jo E.K., Cho Y.L. et al. Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus. Antimicrob. Agents Chemother., 2017, 61, pp. e02752-e02816.
34. Lan S.H., Lin W.T., Chang S.P., Lu L.C., Chao C.M., Lai C.C., Wang J.H. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel), 2019, vol. 8, no. 3, pp. 137. https://doi.org/10.3390/antibiotics8030137
35. Lee J.Y., Shin J., Shin J.H., Chung J.W. In Vitro activity of tedizolid and linezolid against Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Antimicrobial Agents and Chemotherapy, 2017, no. 61, pp. e01939. https://doi.org/10.1128/AAC.0193918
36. Lee S.M., Choi S.C., Mun K.R., Seo J.Y., Cho Y.L., Shim T.S., Lim H.S. Pharmacokinetic and pharmacodynamic modeling analysis of delpazolid (LCB01-0371) in adult patients with pulmonary tuberculosis. J. Clin. Pharmacol., 2024, vol. 64, no. 7, pp. 849-859. https://doi.org/10.1002/jcph.2424
37. Michalik M., Lorenc T., Marcinkowski K., Muras M., Mikszta N., Mikszta J., Kantor K., Marcinkowska J. Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. GMS Hyg. Infect. Control., 2025, no. 20, pp. 33. https://doi.org/10.3205/dgkh000562
38. Michalska K., Lewandowska K., Mizera M., Bocian W., Pałys B., Cielecka-Piontek J. Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid. J. Mol. Struct., 2020, no. 1217, pp. 128396 https://doi.org/10.1016/j.molstruc.2020.128396
39. MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for contezolid and contezolid acefosamil. MicuRx Pharmaceuticals, Published 18.12.2022. Available: https://www.micurx. com/1641.html Accessed June 06, 2025
40. Milosevic T.V., Payen V.L., Sonveaux P., Muccioli G.G., Tulkens P.M., Van Bambeke F. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes antimicrob agents. Chemother., 2018, vol. 62, no. 3, pp. e01599-01617. https://doi.org/ 10.1128/AAC.01599-17
41. Molina-Torres C.A., Barba-Marines A., Valles-Guerra O., Ocampo-Candiani J., Cavazos-Rocha N., Pucci M.J., Castro-Garza J., Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann. Clin. Microbiol. Antimicrob., 2014, no. 13, pp. 13. https://doi.org/10.1186/1476-0711-13-13
42. Negatu D.A., Aragaw W.W., Cangialosi J., Dartois V., Dick T. Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections. Antimicrob. Agents Chemother., 2023, vol. 67, no. 4, pp. e0165522. https://doi.org/10.1128/aac.01655-22
43. Poon Y.K., La Hoz R.M., Hynan L.S., Sanders J., Monogue M.L. Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients. Open Forum Infect. Dis., 2021, vol. 8, no. 4, pp. ofab093. https://doi.org/10.1093/ofid/ofab093
44. Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.M., Shinabarger D., Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother., 2008, vol. 52, no. 12, pp. 4442-4447. https://doi.org/10.1128/AAC.00859-08
45. Shaw T.D., Smyth M., Turner G., Hunter M. Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection. J. Clin. Tuberc. Other Mycobacter. Dis., 2021, no. 24, pp. 100261. https://doi.org/10.1016/j.jctube.2021.100261
46. Soriano A., Miró O., Mensa J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med., 2005, vol. 353, no. 21, pp. 2305-2306. https://doi.org/10.1056/NEJM200511243532123
47. Srivastava S., Cirrincione K.N., Deshpande D., Gumbo T. Tedizolid, faropenem, and moxifloxacin combination with potential activity against nonreplicating Mycobacterium tuberculosis. Front Pharmacol., 2021, no. 11, pp. 616294. https://doi.org/10.3389/fphar.2020.616294
48. Srivastava S., Wang J.Y., Magombedze G., Chapagain M., Huang H.L., Deshpande D., Heysell S.K., Pasipanodya J.G., Gumbo T. Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii. Antimicrob. Agents Chemother., 2023, vol. 95, no. 5, pp. e01553-e1620. https://doi.org/10.1128/AAC.01553-20.24
49. Srivastava S., Deshpande D., Nuermberger E., Lee P.S., Cirrincione K., Dheda K., Gumbo T. The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis. Clinical Infection Diseases, 2018, vol. 67, s. 3, pp. 336-341. https://doi.org/10.1093/cid/ciy626
50. Strydom N., Ernest J.P., Imperial M., Solans B.P., Wang Q., Tasneen R., Tyagi S., Soni H., Garcia A., Bigelow K., Gengenbacher M., Zimmerman M., Xie M., Sarathy J.P., Yang T.J., Dartois V., Nuermberger E.L., Savic R.M. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat. Commun., 2024, vol. 15, no. 1, pp. 7311. https://doi.org/10.1038/s41467-024-50781-4
51. Study Protocol NCT04550832 Available: ClinicalTrials.gov Accessed September 16, 2025
52. Tasneen R., Betoudji F., Tyagi S., Li S.Y., Williams K., Converse P.J., Dartois V., Yang T., Mendel C.M., Mdluli K.E., Nuermberger E.L. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob. Agents Chemother., 2015, vol. 60, no. 1, pp. 270-277. https://doi.org/10.1128/AAC.01691-15
53. Wallis R.S., Dawson R., Friedrich S.O., Venter A., Paige D., Zhu T., Silvia A., Gobey J., Ellery C., Zhang Y., Eisenach K., Miller P., Diacon A.H. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One, 2014, vol. 9, no. 4, pp. e94462. https://doi.org/10.1371/journal.pone.0094462
54. Wallis R.S., Jakubiec W.M., Kumar V., Silvia A.M., Paige D., Dimitrova D., Li X., Ladutko L., Campbell S., Friedland G., Mitton-Fry M., Miller P.F. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis., 2010, vol. 202, no. 5, pp. 745-751. https://doi.org/10.1086/655471
55. Wei L., Hong M., Lu M., Qian Y., Li Q., Tang N., Li H., Chang Y., Qiu Y. Safety evaluation of contezolid (MRX-I) versus linezolid in Sprague-Dawley rats. Drugs R D, 2025, vol. 25, no. 2, pp. 127-140. https://doi.org/10.1007/s40268-025-00504
56. Wen S., Gao X., Zhao W., Huo F., Jiang G., Dong L., Zhao L., Wang F., Yu X., Huang H. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int. J. Infect. Dis., 2021, no. 109, pp. 253-260. https://doi.org/10.1016/j.ijid.2021.06.055
57. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment: 2022 update. Geneva, World Health Organization, 2022. ISBN 978-92-4-006312-9.
58. World Health Organization. Global Tuberculosis Report 2023: Drug-resistant TB burden. Geneva, WHO, 2023. Available: who.int›publications/i/item/9789240083851 Accessed July 7, 2025
59. Yu X., Huo F., Wang F., Wen S., Jiang G., Xue Y., Dong L., Zhao L., Zhu R., Huang H. In vitro antimicrobial activity comparison of linezolid, tedizolid, sutezolid and delpazolid against slowly growing mycobacteria isolated in Beijing, China. Infect. Drug Resist., 2021, no. 14, pp. 4689-4697. https://doi.org/10.2147/IDR.S332835
60. Yuan S., Shen D.D., Bai Y.R., Zhang M., Zhou T., Sun C., Zhou L., Wang S.Q., Liu H.M. Oxazolidinone: A promising scaffold for the development of antibacterial drugs. Eur. J. Med. Chem., 2023, no. 250, pp. 115239. https://doi.org/10.1016/j.ejmech.2023.115239
61. Yuste J.R., Berto J., Del Pozo J.L., Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J. Antimicrob. Chemother., 2017, vol. 72, no. 2, pp. 625-628. https://doi.org/10.1093/jac/dkw484
62. Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F., Gorityala B., Lagacé-Wiens P.R., Rubinstein E., Walkty A., Gin A.S., Gilmour M., Hoban D.J., Lynch J.P., Karlowsky J.A. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs, 2015, vol. 75, no. 3, pp. 253-70. https://doi.org/10.1007/s40265-015-0352-7
63. Zhang M., Sala C., Dhar N., Vocat A., Sambandamurthy V.K., Sharma S., Marriner G., Balasubramanian V., Cole S.T. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 6, pp. 3217-3223. https://doi.org/10.1128/AAC.02410-14
Review
For citations:
Gayda A.I., Mozhokina G.N., Pereverzeva E.R., Romanova M.I., Abramchenko A.V., Samoylova A.G. Searching for Ideal Oxazolidinone for Treatment of Tuberculosis. Tuberculosis and Lung Diseases. 2026;104(1):114-125. (In Russ.) https://doi.org/10.58838/2075-1230-2026-104-1-114-125
Views:
280
JATS XML
Email this article 